Souhaitez-vous accéder aux communiqués récents ?

BioNTech SE präsentiert neue klinische Daten und Studienupdates zu Programmen in der spätklinischen Entwicklung sowie zu innovativen Kombinationsprogrammen

STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer

Les résultats de Topline seront présentés par le Pr Alexandra Leary, PhD, le 30 mai 2026 au congrès annuel de l’American Society of Clinical Oncology (ASCO) à ChicagoOSE Immunotherapeutics organisera...

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of...

ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company...

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients ...

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with...

SAN MATEO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Asher Biotherapeutics (Asher Bio), a clinical-stage biotechnology company developing precisely-targeted immunotherapies for cancer, today...

   At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a...